Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07810634) titled 'Pyrotinib for HER2-Positive Advanced Breast Cancer Previously Treated With Trastuzumab and Pertuzumab' on Sept. 3.

Study Type: Observational

Primary Sponsor: Beijing 302 Hospital

Condition: Breast Cancer

Intervention: Drug: Pyrotinib 400mg

Recruitment Status: Not recruiting

Date of First Enrollment: September 2, 2026

Target Sample Size: 200

Countries of Recruitment: China

To know more, visit https://clinicaltrials.gov/study/NCT07810634

Published by HT Digital Content Services with permission from Health Daily Digest....